Emergent BioSolutions Inc (EBS.N)
22 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2012||Executive Chairman of the Board|
|57||2012||President, Chief Executive Officer, Director|
|59||2012||Chief Financial Officer, Executive Vice President, Administration, Treasurer|
|46||2017||Executive Vice President - Business Operations|
|61||2014||Lead Independent Director|
- BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67
- BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million
- BRIEF-Emergent Biosolutions reports third quarter results
- BRIEF-Emergent Biosolutions awarded U.S. Department of State contract valued at up to $25 mln to supply nerve agent antidote auto-injector
- BRIEF-Emergent Biosolutions completes acquisition of Raxibacumab from GSK